These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Human papillomavirus vaccines in development: if they're successful in clinical trials, how will they be implemented? Shaw AR Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S246-8. PubMed ID: 16213009 [TBL] [Abstract][Full Text] [Related]
24. Introducing human papillomavirus vaccines - questions remain. Paavonen J; Lehtinen M Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882 [TBL] [Abstract][Full Text] [Related]
25. Prevention strategies against human papillomavirus in males. Garland SM Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347 [TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus infection in adolescent and young women. Lawson MA Mo Med; 2008; 105(1):42-6. PubMed ID: 18300604 [TBL] [Abstract][Full Text] [Related]
28. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Dasbach EJ; Elbasha EH; Insinga RP Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585 [TBL] [Abstract][Full Text] [Related]
30. Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine? Dillner J; Brown DR Expert Rev Mol Med; 2004 Apr; 6(9):1-21. PubMed ID: 15096282 [TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus vaccines in HIV-positive men and women. De Vuyst H; Franceschi S Curr Opin Oncol; 2007 Sep; 19(5):470-5. PubMed ID: 17762573 [TBL] [Abstract][Full Text] [Related]
33. Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands. Mollers M; Boot Hein J; Vriend Henrike J; King Audrey J; van den Broek Ingrid VF; van Bergen Jan EA; Brink Antoinette AT; Wolffs Petra FG; Hoebe Christian JP; Meijer Chris JL; van der Sande Marianne AB; de Melker Hester E Vaccine; 2013 Jan; 31(2):394-401. PubMed ID: 23146675 [TBL] [Abstract][Full Text] [Related]
34. Impact of human papillomavirus vaccination depends on effective vaccination strategy. Lehtinen M; Paavonen J Int J Cancer; 2009 Sep; 125(6):1490-1. PubMed ID: 19507251 [No Abstract] [Full Text] [Related]
35. Human papillomavirus-specific immune therapy: failure and hope. Nieto K; Gissmann L; Schädlich L Antivir Ther; 2010; 15(7):951-7. PubMed ID: 21041909 [TBL] [Abstract][Full Text] [Related]
36. Can male vaccination reduce the burden of human papillomavirus-related disease in the United States? Low GM; Attiga YS; Garg G; Schlegal R; Gallicano GI Viral Immunol; 2012 Jun; 25(3):174-86. PubMed ID: 22691099 [TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus and genital cancer. Rapose A Indian J Dermatol Venereol Leprol; 2009; 75(3):236-43; quiz 243-4. PubMed ID: 19439875 [TBL] [Abstract][Full Text] [Related]
38. A Contemporary Review of HPV and Penile Cancer. Stratton KL; Culkin DJ Oncology (Williston Park); 2016 Mar; 30(3):245-9. PubMed ID: 26984219 [TBL] [Abstract][Full Text] [Related]
39. Vaccines for human papillomavirus infection: a critical analysis. Nath AK; Thappa DM Indian J Dermatol Venereol Leprol; 2009; 75(3):245-53; quiz 254. PubMed ID: 19439876 [TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec; 2014 Oct; 89(43):465-91. PubMed ID: 25346960 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]